+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Leukemia Therapeutics Market Research Report by Type, by Molecule Type, by Mode of Administration, by Gender - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4896743
  • Report
  • June 2020
  • Region: Global
  • 209 pages
  • 360iResearch™
UP TO OFF
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Leukemia Therapeutics Market to Grow USD 17,234.53 Million by 2025, at a CAGR of 5.98%

FEATURED COMPANIES

  • Biogen
  • Celgene Corporation
  • Eisai C.
  • F. Hoffmann-La Roche AG
  • Genzyme Corporation
  • GlaxoSmithKline plc
  • MORE
The Global Leukemia Therapeutics Market is expected to grow from USD 12,157.38 Million in 2019 to USD 17,234.53 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.98%.

Market Segmentation & Coverage:

This research report categorizes the Leukemia Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Type, the Leukemia Therapeutics Market is examined across Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia.

On the basis of Treatment Type, the Leukemia Therapeutics Market is examined across Chemotherapy and Targeted Drugs & Immunotherapy.

On the basis of Molecule Type, the Leukemia Therapeutics Market is examined across Biologics and Small Molecules.

On the basis of Mode of Administration, the Leukemia Therapeutics Market is examined across Injectable Mode and Oral Mode.

On the basis of Gender, the Leukemia Therapeutics Market is examined across Female and Male.

On the basis of Geography, the Leukemia Therapeutics Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Leukemia Therapeutics Market including Biogen, Bristol Myers Squibb Company, Celgene Corporation, Eisai C., F. Hoffmann-La Roche AG, Genzyme Corporation, GlaxoSmithKline plc, Novartis AG, and Pfizer Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Leukemia Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Leukemia Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Leukemia Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Leukemia Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Leukemia Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Leukemia Therapeutics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Leukemia Therapeutics Market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biogen
  • Celgene Corporation
  • Eisai C.
  • F. Hoffmann-La Roche AG
  • Genzyme Corporation
  • GlaxoSmithKline plc
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Type Outlook
3.3. Treatment Type Outlook
3.4. Molecule Type Outlook
3.5. Mode of Administration Outlook
3.6. Gender Outlook
3.7. Geography Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Leukemia Therapeutics Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Leukemia Therapeutics Market, By Type
7.1. Introduction
7.2. Acute Lymphocytic Leukemia
7.3. Acute Myeloid Leukemia
7.4. Chronic Lymphocytic Leukemia
7.5. Chronic Myeloid Leukemia

8. Global Leukemia Therapeutics Market, By Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.3. Targeted Drugs & Immunotherapy

9. Global Leukemia Therapeutics Market, By Molecule Type
9.1. Introduction
9.2. Biologics
9.3. Small Molecules

10. Global Leukemia Therapeutics Market, By Mode of Administration
10.1. Introduction
10.2. Injectable Mode
10.3. Oral Mode

11. Global Leukemia Therapeutics Market, By Gender
11.1. Introduction
11.2. Female
11.3. Male

12. Americas Leukemia Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Leukemia Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. South Korea
13.10. Thailand

14. Europe, Middle East & Africa Leukemia Therapeutics Market
14.1. Introduction
14.2. France
14.3. Germany
14.4. Italy
14.5. Netherlands
14.6. Qatar
14.7. Russia
14.8. Saudi Arabia
14.9. South Africa
14.10. Spain
14.11. United Arab Emirates
14.12. United Kingdom

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding

16. Company Usability Profiles
16.1. Biogen
16.2. Bristol Myers Squibb Company
16.3. Celgene Corporation
16.4. Eisai C.
16.5. F. Hoffmann-La Roche AG
16.6. Genzyme Corporation
16.7. GlaxoSmithKline plc
16.8. Novartis AG
16.9. Pfizer Inc.

17. Appendix
17.1. Discussion Guide
17.2. Edition Details
17.3. License Details
17.4. Pricing Details
Note: Product cover images may vary from those shown
3 of 3
  • Biogen
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eisai C.
  • F. Hoffmann-La Roche AG
  • Genzyme Corporation
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll